Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users

doi:10.3748/wjg.v13.i16.2357

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2747)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-5) series.

Item

Count

PDF

330

HTML

2229

Tables (1-5)

188

Sum=2747

Apr 28, 2007 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Apr 28, 2007; 13(16): 2357-2362
Published online Apr 28, 2007. doi: 10.3748/wjg.v13.i16.2357

Table 1 Prevalence of HBV, HCV, HIV, HDV, HGV and HCMV in IDU and controls

Group	HBsAg	Anti-HBc	HBeAg	Anti-HCV	Anti-HIV	HDV-Ag	Anti-HGV	HCMV-IgM
IDU	24 (5.91)^a	148 (36.45)^b	12 (3.96)	283 (69.7)^b	192 (47.3)^b	9 (2.22)	8 (1.97)	14 (3.45)
Control	1 (0.98)	18 (17.65)	2 (1.96)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

^aP < 0.05,

^bP < 0.01 vs control.

Table 2 CD percentages and cytokine level in IDU and controls (mean ± SD )

Group	n	CD3 (%)	CD4 (%)	CD8 (%)	PHA-induced cytokineIFN-γ(ng/L)	PHA-induced cytokineIL-4 (ng/L)	Serum cytokineIL-2 (μg/L)	Serum cytokineIL-4 (μg/L)
IDU	214	57.96 ± 4.42^b	41.63 ± 4.0^b	29.19 ± 2.67	286.9 ± 45.79^b	20.86 ± 1.54^a	1.74 ± 1.34^b	9.36 ± 5.48^b
Control	102	66.50 ± 9.42	44.90 ± 8.56	30.10 ± 6.89	785.3 ± 213	28.90 ± 10.8	3.80 ± 1.59	0.78 ± 0.33

^aP < 0.05,

^bP < 0.01 vs control.

Table 3 Correlation of HBV activity and HIV infection

Group	HBV-DNA-positive^b	HBV-DNA-negative	HBeAg-positive^b	HBeAg-negative	HBsAg-positive^b	HBsAg-negative
HIV-positive	15	14	11	18	17	12
HIV-negative	2	117	1	118	7	112

^bP < 0.01 vs HIV-negative.

Table 4 CD percentages and cytokine level in IDU with HIV and HBV co-infection (mean ± SD)

Group	n	CD3 (%)	CD4 (%)	CD8 (%)	CD4/CD8	IFN-γ(ng/L)	IL-4 (ng/L)
Negative¹	40	56.80 ± 4.42	41.90 ± 4.16	29.08 ± 2.85	1.44 ± 0.13	288.01 ± 40.03	20.76 ± 1.87
HBV infection	29	58.85 ± 4.13	41.57 ± 4.21	29.16 ± 2.65	1.43 ± 0.14	289.82 ± 42.56	20.94 ± 1.33
HIV infection	27	54.27 ± 4.23^b	39.49 ± 3.47^a	28.98 ± 3.11	1.36 ± 0.15^b	265.43 ± 38.71^a	20.23 ± 1.34
HIV⁺HBV-DNA^-	30	53.95 ± 3.77^b	39.36 ± 2.86^b	28.91 ± 2.35	1.36 ± 0.13^b	263.57 ± 43.65^a	20.84 ± 1.56
HIV⁺HBV-DNA⁺	15	53.68 ± 4.41^a	39.22 ± 3.53^a	28.67 ± 3.14	1.37 ± 0.15^b	262.83 ± 38.74^a	20.61 ± 1.49

^aP < 0.05,

^bP < 0.01 vs negative cases.

¹Viral infection markers were not discovered in IDU.

Table 5 CD percentages and cytokine level in IDU with HIV and HCV co-infection (mean ± SD)

Group	n	CD3 (%)	CD4 (%)	CD8 (%)	CD4/CD8	IFN-γ(ng/L)	IL-4 (ng/L)
Negative¹	40	56.80 ± 4.42	41.9 ± 4.16	29.08 ± 2.85	1.44 ± 0.13	288.01 ± 40.03	20.76 ± 1.87
HCV infection	45	58.23 ± 4.70	41.42 ± 3.65	29.33 ± 2.52	1.41 ± 0.12	282.86 ± 54.77	20.88 ± 1.42
HIV infection	27	54.27 ± 4.23^b	39.49 ± 3.47^a	28.98 ± 3.11	1.36 ± 0.15^b	265.43 ± 38.71^a	20.23 ± 1.34
HIV⁺HCV-RNA^-	40	54.02 ± 3.66^b	39.29 ± 2.91^b	28.81 ± 2.42	1.36 ± 0.13^b	261.59 ± 43.68^a	20.46 ± 1.38
HIV⁺HCV-RNA⁺	25	53.82 ± 3.15^b	39.51 ± 2.91*	28.58 ± 2.53	1.38 ± 0.13^b	263.57 ± 43.65^a	20.84 ± 1.56

^aP < 0.05,

^bP < 0.01 vs negative cases.

¹Viral infection markers were not discovered in IDU.

Citation: Li JR, Gong RY, Tian KL, Wang J, Wang YX, Huang HJ. Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users. World J Gastroenterol 2007; 13(16): 2357-2362
URL: https://www.wjgnet.com/1007-9327/full/v13/i16/2357.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i16.2357